linjc16/ctgov huggingface dataset:
Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.

Official Title
-----------------
An Exploratory Clinical Trial to Evaluate the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation

Conditions
-----------------
Liver Cirrhosis, Chronic Hepatitis B

Intervention / Treatment
-----------------
* Other: Blood Sample Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female ≤18 years old Patients who understand the informed consent form and signed the form voluntarily Patients who underwent liver transplantation due to HBV related disease and will be treated for prevention of hepatitis B relapse after liver transplantation Exclusion Criteria: Multi-organ recipient or reimplantation IgA Deficiency Serious nephropathy Serious cardiovascular system failure within 6 months Ischemic or hemolytic anemia Condition of immunosuppression and immunodeficiency Hypersensitivity or allergic to blood products HIV or HCV positive Participation to other clinical trial within 3 months Pregnancy or breast feeding Those who the investigator determines inappropriate to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hepabig<br>Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation | Other: Blood Sample Collection<br>* Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anti-HBs titer | The anti-HBs titer is measured on the day of LT, day 1, week 1, week 4, week 12 and week 24, to determine the pharmacokinetic characteristic of Hepabig I.V. injection | up to 6 months |
Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence

Study Overview
=================
Brief Summary
-----------------
This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine hstopathology imaging based algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

Detailed Description
-----------------
Non-invasive and precise prediction for survivals of glioma patients is challenging. With the development of artificial intelligence, much more potential lies in the histopathology images of HE slices in primary gliomas could be excavated to aid prediction of patients' prognosis in the frame of molecular pathology of gliomas. The creation of a registry for primary glioma with detailed survival data, molecular pathology, histopathology image data and with sufficient sample size for deep learning (>1000) provides opportunities for personalized prediction of survival of glioma patients with non-invasiveness and precision.

Official Title
-----------------
Histopathology Images Based Survival Prediction of Patients With Primary Glioma Using Deep Learning or Machine Learning

Conditions
-----------------
Glioma

Intervention / Treatment
-----------------
* Diagnostic Test: Histopathology images based survival prediction for glioma patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have radiologically and histologically confirmed diagnosis of primary glioma Life expectancy of greater than 3 months Must receive tumor resection Signed informed consent Exclusion Criteria: No gliomas No sufficient amount of tumor tissues for detection of molecular pathology Patients who are pregnant or breast feeding Patients who are suffered from severe systematic malfuctions

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Histopathology images based survival prediction for glioma patients|Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC of survival prediction performance | AUC of survival prediction performance=sensitivity+specificity-1 | up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prognosis, Histopathology imaging, Deep Learning, Machine Learning
Diet Patterns in IBD in Central Texas

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to understand the diet patterns, preferences, and impact of diet on daily living in our patients with IBD in Central Texas.

Official Title
-----------------
A Cross-sectional Assessment of Diet in Patients With IBD in Central Texas

Conditions
-----------------
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

Intervention / Treatment
-----------------
* Other: NO INTERVENTION


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patient 18years of age or older with inflammatory bowel disease Exclusion Criteria: unwilling to participate diagnosis of IBD unable to be verified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: NO INTERVENTION|There is no intervention for this study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diet patterns |  | 6 months | 
| diet preferences |  | 6 months | 
| diet impact |  | 6 months |
The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis

Study Overview
=================
Brief Summary
-----------------
Hemoptysis is defined as the expectoration of blood from respiratory tract, a spectrum that varies from blood-streaking of sputum to coughing up large amounts of pure blood. Massive hemoptysis variably defined as the expectoration of 100-600 ml over 24-h period. The most common site of bleeding is the tracheobronchial tree, which can be affected by inflammation (acute or chronic bronchitis, bronchiectasis) or by neoplasm ( bronchogenic carcinoma, endobronchial metastatic carcinoma, bronchial carcinoid tumor). The bronchial arteries, which originate either from aorta or from intercostal arteries, and are part of the high-pressure systemic circulation, are the source of bleeding in bronchitis or bronchiectasis or endo bronchial tumors.

Conditions
-----------------
Hemoptisis

Intervention / Treatment
-----------------
* Drug: tranexamic acid
* Drug: tranexamic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 Hemodynamicaly stable Hemoptysis of varying etiologies Coumadin treatment will be switched to clexane or heparine Exclusion Criteria: Age < 18 Hemodinamicaly unstable Massive hemoptysis ( > 200 ml / day) Renal failure: creatinine > 3, renal replacement treatment Hepatic failure: bilirubin > 2 mg/dl, AST > 3 of upper normal limit level Coagulation disorders, INR> 2. Hypesensitivity to tranexamic acid Pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: tranexamic acid-500 mg/5 ml 3-4 times a day<br>tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day | Drug: tranexamic acid<br>* 500 mg/5 ml 3-4 times a day<br>|
| Placebo Comparator: tranexamic<br>placebo arm | Drug: tranexamic acid<br>* 500 mg/5 ml 3-4 times a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bleeding stops |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemoptisis, bleeding, tranexamic acid
Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect

Study Overview
=================
Brief Summary
-----------------
Background: Three-dimensional echocardiographic image for atrial septal defect (ASD) is useful for evaluation of defect size and shape. The investigators suggested optimal device size using three-dimensional transesophageal echocardiographic image and our formula in previous study. Purpose: In this study, the investigators seek to predict the correct device size and confirm the accuracy of the formula that we made before device closure in ASD patients.

Conditions
-----------------
Atrial Septal Defect, Successful Device Closure

Intervention / Treatment
-----------------
* Device: Transcatheter device closure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 year-old Susceptible indication for atrial septal defect closure Potential candidate for device closure Exclusion Criteria: Poor candidate for device closure: multiple ASDs, ect Other heart disease requiring open heart surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: transcatheter device closure<br>Choosing device size using three dimensional image and the formula without sizing balloon | Device: Transcatheter device closure<br>* Closure of atrial septal defect with device choosing device size with 3D image and the formula we do not use sizing balloon for choosing of the device size<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful device implantation |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procedure time |  | during procedure |
Observational Study of Infants Born at 34 to 37 Weeks of Gestation Until the Age of 1 Year

Study Overview
=================
Brief Summary
-----------------
Late preterm infants are at an increased risk for short and long term morbidity (during the 1st year of life, their neurodevelopmental status may also be delayed as compared to infants born at term). The term near term infants is probably a deceiving one.

Detailed Description
-----------------
The study will include all near term infants born at 3 Israeli medical centers during a one year period.

Official Title
-----------------
Late Preterm Infants:Clinical Course and Outcome From Birth Through Out the First Year of Life.

Conditions
-----------------
Respiratory Distress, Hypoglycemia, Feeding Intolerance, Jaundice, Hypothermia, Developmental Delay

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age 34wks- 37wks Singleton Without chromosomal abnormalities or malformations Exclusion Criteria: No chromosomal abnormalities Malformations

Ages Eligible for Study
-----------------
Minimum Age: 1 Hour
Maximum Age: 30 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neurodevelopmental, health and growth status in late preterm infants vs. controls within the first year of life |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
late preterm infants, near term infants, outcome
Acute Myocardial Infarction and Acute Cerebral Infarction (AMIAC) Registry and Follow-up

Study Overview
=================
Brief Summary
-----------------
A registry of consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction were conducted at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016. The adverse clinical outcomes, including all-cause mortality, were followed from the date of admission for acute myocardial infarction or acute cerebral infarction until study end (December 31, 2016). All-cause mortality, including the date of death, was identified from the electronic hospitalization data, phone follow-up, and confirmed by the household registration (HUKOU) system, a record of registration required by law in China. Baseline characteristics, including major treatment of acute myocardial infarction or acute cerebral infarction, estimated glomerular filtration rate (eGFR) and proteinuria, were collected. Demographic data were determined from the electronic hospitalization data and electronic hospital discharge records. All comorbid conditions were identified using International Statistical Classification of Diseases, Tenth Revision (ICD-10), coding algorithms applied to electronic physician claims and electronic hospital discharge records. Life style (smoking), treatment regimen at discharge, including angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), were determined from the electronic hospitalization data.

Official Title
-----------------
The Registry and Follow-up of Patients With Acute Myocardial Infarction or Acute Cerebral Infarction

Conditions
-----------------
Myocardial Infarction, Cerebral Infarction, Chronic Kidney Diseases, Mortality

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction Exclusion Criteria: lacunar infarction
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acute cerebral infarction<br>the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction | |
| acute myocardial infarction<br>the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality | all-cause mortality | follow up until the study end (May 2018,Anticipated) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| kidney outcome | ESRD or 50%eGFR decline | follow up until the study end (May 2018,Anticipated) |
Genotypic and Phenotypic Correlates of Resistance to Aspirin

Study Overview
=================
Brief Summary
-----------------
The study seeks to identify genomic markers associated with aspirin resistance.

Detailed Description
-----------------
Not desired

Official Title
-----------------
Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population

Conditions
-----------------
Platelet Dysfunction Due to Aspirin

Intervention / Treatment
-----------------
* Drug: aspirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers 40 to 80 years old willing to sign consent and take 81 mg of aspirin for 7 - 10 days and return for laboratory testing. Exclusion Criteria: Patient requiring more than 81 mg aspirin daily Known GI bleeding attributed to ASA Active peptic ulcer disease or history within the last year Known aspirin allergy Current use of: warfarin, heparin, NSAIDs (except aspirin), clopidogrel, dipyridamole, fish-oil/omega 3 supplements, Women of childbearing potential who are pregnant, planning to become pregnant or nursing.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Aspirin<br>All subjects took 7-10 days of 81 mg aspirin | Drug: aspirin<br>* aspirin 81mg, 7-10 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Whole Blood Coagulation | Whole blood coagulation after stimulation with arachidonic acid, as measured in the VerifyNow Aspirin system (Accumetrics). Aspirin response units (ARU) are the residual coagulation present in patients taking aspirin. The higher the ARU, the greater residual coagulation (resistance) to the aspirin effect. | Single measurement at 7-10 days after beginning aspirin | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genomic markers, aspirin resistance
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.

Official Title
-----------------
Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.

Conditions
-----------------
Cerebrovascular Accident, Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinically defined lacunar syndrome 3 months before inclusion small deep infarct on diffusion MRI (Diffusion Weighted Imaging) no atherothrombotic, cardio-embolic, or other rarer cause. Exclusion Criteria: patients with past coronary event contra-indication for assessment of vasomotor reactivity patients being on statin therapy at the time of brain infarction contra-indication for statin therapy patient still under statin therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atorvastatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independent vasomotoricity of humeral and / or common carotid artery (according to validation study) in lacunar patients. |  |  |
CUHK Jockey Club HOPE 4 Care Programme - Ankle Robot

Study Overview
=================
Brief Summary
-----------------
The Hong Kong Jockey Club Charities Trust has supported CUHK to launch a three-year project 'CUHK Jockey Club HOPE4Care Programme' to implement four evidence-based advanced rehabilitation technologies in 40 local elderly day care centres and rehabilitation centres, to benefit the community. The Exoskeleton Ankle Robot is a robot-assisted Ankle-Foot-Orthosis to facilitate gait training of person after stroke with drop foot.

Official Title
-----------------
CUHK Jockey Club Tech-Based Stroke Rehabilitation Programme for Elderly Centre - Interactive Exoskeleton Ankle Robot

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: Ankle Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have the ability to walk on the ground independently or with one personal assistance with or without walking aids able to understand simple commends Exclusion Criteria: have other neurological, neuromuscular, and orthopedic diseases uncontrolled cardiovascular or respiratory disorders moderate to severe contractures in the lower extremities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ankle Group<br>Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm. | Device: Ankle Group<br>* Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fugl-Meyer Assessment Lower Extremity (FMA-LE) |  | 3-month follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional Ambulation Classification (FAC) |  | 3-month follow-up | 
| Modified Ashworth Scale (MAS) |  | 3-month follow-up | 
| Berg Balance Scale (BBS) |  | 3-month follow-up | 
| Timed 10-Meter Walk Test (10MWT) |  | 3-month follow-up | 
| 6 Minute Walk Test (6MWT) |  | 3-month follow-up |